Krystal Biotech Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 521.07, 662.6, 847.87, 1330.94, 1712.2 ], "ebit_estimate": [ 241.53, 335.55, 551.27, 898.58, 1237 ], "ebitda_estimate": [ 252.73, 358.33, 513.1, null, null ], "net_income_estimate": [ 231.07, 308.6, 462.34, 784.9, 1086.06 ], "per_share_eps_estimate": [ 7.63, 9.95, 13.89, 13.92, 17.55 ], "eps_nri_estimate": [ 7.68, 9.79, 13.89, 13.92, 17.55 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ 275.69, 385.51, 558.12, 1101.38, 1502.65 ], "operating_cash_flow_per_share_estimate": [ 10.22, 11.77, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ 25.34, 21.18, 17.84, null, null ], "gross_margin_estimate": [ 95, 95, 95, 95, 95 ], "operating_cash_flow_estimate": [ 311.78, 359.07, null, null, null ], "pettm_estimate": [ 47.94, 36.77, 26.33, 26.28, 20.84 ], "long_term_growth_rate_mean": 26.73, "long_term_revenue_growth_rate_mean": "29.39", "future_per_share_eps_estimate_growth": 27.01, "future_eps_nri_estimate_growth": 26.73, "future_revenue_estimate_growth": 29.39, "future_ebit_estimate_growth": 49.42, "future_ebitda_estimate_growth": 45.01, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 31.41, "future_pretax_income_estimate_growth": 42.99, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 0.29, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 124.21, 135.01, 145.96, 146.69, 163.84, 185.17, 215.83 ], "ebit_estimate": [ 56.5, 63.14, 71.58, null, null, null, null ], "ebitda_estimate": [ 57.59, 65.14, 73.51, null, null, null, null ], "net_income_estimate": [ 52.84, 58.3, 64.43, null, null, null, null ], "per_share_eps_estimate": [ 1.72, 1.93, 2.16, 2.72, 2.49, 2.96, 3.65 ], "eps_nri_estimate": [ 1.74, 1.95, 2.13, 2.72, 2.49, 2.96, 3.65 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ 71.11, 80.14, 90.1, null, null, null, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ 33.79, 35.5, 37.36, null, null, null, null ], "gross_margin_estimate": [ 95, 95, 95, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 42.87, 39.33, 35.41, 30.95, null, null, null ], "long_term_growth_rate_mean": 26.73, "long_term_revenue_growth_rate_mean": "29.39", "future_per_share_eps_estimate_growth": 27.01, "future_eps_nri_estimate_growth": 26.73, "future_revenue_estimate_growth": 29.39, "future_ebit_estimate_growth": 49.42, "future_ebitda_estimate_growth": 45.01, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 31.41, "future_pretax_income_estimate_growth": 42.99, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 0.29, "future_operating_cash_flow_per_share_estimate_growth": null }